Diversified Trust Co Has $637,000 Stock Holdings in STERIS plc (NYSE:STE)

Diversified Trust Co raised its holdings in STERIS plc (NYSE:STE) by 13.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,101 shares of the medical equipment provider’s stock after buying an additional 365 shares during the period. Diversified Trust Co’s holdings in STERIS were worth $637,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. West Coast Financial LLC raised its holdings in shares of STERIS by 2.8% in the third quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock valued at $398,000 after purchasing an additional 45 shares during the last quarter. SkyView Investment Advisors LLC increased its stake in STERIS by 1.6% in the 3rd quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock valued at $765,000 after buying an additional 51 shares during the last quarter. Waterloo Capital L.P. lifted its position in shares of STERIS by 3.2% during the 2nd quarter. Waterloo Capital L.P. now owns 1,916 shares of the medical equipment provider’s stock worth $421,000 after buying an additional 59 shares in the last quarter. Central Pacific Bank Trust Division boosted its stake in shares of STERIS by 65.5% in the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 76 shares during the last quarter. Finally, Metis Global Partners LLC grew its holdings in shares of STERIS by 1.6% in the third quarter. Metis Global Partners LLC now owns 5,450 shares of the medical equipment provider’s stock valued at $1,322,000 after acquiring an additional 84 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on STE. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research report on Monday, November 18th. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Finally, Stephens reaffirmed an “overweight” rating and issued a $260.00 price target on shares of STERIS in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, STERIS has a consensus rating of “Moderate Buy” and an average target price of $262.50.

Insider Transactions at STERIS

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the sale, the senior vice president now directly owns 11,372 shares in the company, valued at $2,471,363.04. This represents a 12.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.14% of the company’s stock.

STERIS Stock Performance

Shares of STE stock opened at $205.85 on Friday. STERIS plc has a 12 month low of $197.82 and a 12 month high of $248.24. The stock has a market capitalization of $20.32 billion, a P/E ratio of 47.00 and a beta of 0.84. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $213.53 and its 200 day moving average is $225.04.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.33 billion. During the same period last year, the company earned $2.03 earnings per share. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, sell-side analysts anticipate that STERIS plc will post 9.1 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th were given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.11%. The ex-dividend date of this dividend was Tuesday, November 19th. STERIS’s dividend payout ratio is presently 52.05%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.